Literature DB >> 3159712

The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.

A King, K Shannon, I Phillips.   

Abstract

The in-vitro activities of enoxacin and ofloxacin were compared with that of the other new 4-quinolone, ciprofloxacin. All three compounds were highly active against Enterobacteriaceae, Haemophilus influenzae and Neisseria gonorrhoeae (MICs mostly less than 1 mg/l). The other Gram-negative aerobes tested were in general less susceptible, though for Acinetobacter and Pseudomonas species (including aeruginosa) MICs seldom exceeded 8 mg/l. Ofloxacin and ciprofloxacin were more active against Gardnerella vaginalis (MICs 0.5-2 mg/l) than was enoxacin (MICs 8-32 mg/l). Staphylococci were susceptible to ofloxacin (MICs 0.12-1 mg/l) and enoxacin (MICs 0.5-2 mg/l) as well as to ciprofloxacin. Streptococci also were mostly sensitive to the compounds though the MICs of enoxacin (4-64 mg/l) were noticeably higher than those of ofloxacin (1-4 mg/l). Anaerobes were in general susceptible though, as with streptococci, ofloxacin, with activity similar to that of ciprofloxacin, was more active than enoxacin. Variants of Enterobacteriaceae with reduced susceptibility were readily selected in the laboratory with either enoxacin or ofloxacin as the selective agent. The MICs of all the 4-quinolones were usually increased four- to 16-fold for these strains; they could therefore be regarded as remaining susceptible to the newer compounds.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159712     DOI: 10.1093/jac/15.5.551

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens.

Authors:  W R Bowie; C E Shaw; D G Chan; J Boyd; W A Black
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.

Authors:  S Mehtar; Y Drabu; P Blakemore
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

5.  Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.

Authors:  J Guibert; D Destrée; C Konopka; J Acar
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

Review 6.  [Enoxacin: spectrum and activity of its antibacterial effect].

Authors:  A Bauernfeind; H Flamm; H Grimm; H Hahn; F Kayser; W Opferkuch; J Potel; R Malottke; H G Sonntag; W H Traub
Journal:  Infection       Date:  1986       Impact factor: 3.553

7.  In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains.

Authors:  R P Smith; A L Baltch; M C Hammer; J V Conroy
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

9.  Species identification and antibiotic susceptibility testing of enterococci isolated from hospitalized patients.

Authors:  J W Gray; D Stewart; S J Pedler
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.